Arana expands clinical research
Monday, 28 July, 2008
Arana Therapeutics (ASX: AAH) has appointed former Quintiles executive Dr Alan Scott as its new vice president of clinical research.
The Sydney-headquartered biotech, the result of a merger between Peptech and EvoGenix last year, is commencing several new clinical trials in the next 18 months.
Arana's next scheduled clinical trial will be a Phase II rheumatoid arthritis dose-ranging study for its leading anti-inflammatory compound ART621, which is expected to start in the fourth quarter of this year.
Scott holds a PhD from Glasgow University, did a post-doc in biochemistry at Oxford and has held positions in clinical operations and project management in Europe in the pharma, biotech and CRO sectors.
He was director of site start up for Quintiles in the Asia-Pacific region.
'Mini brains' mimic MS myelin damage
The MS organoids give researchers a highly detailed cellular view of myelin destruction...
Fast-aging placentas may contribute to pre-eclampsia
Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...
BioNTech opens mRNA manufacturing facility at La Trobe
Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...
